Drug Chatter -- Tracking biopharma stock chatter

Profile for Dicerna Pharmaceuticals, Inc. (DRNA)

« Back to company index

DRNA Chatter Timeline

Stock Ticker for DRNA

Most Active Tweeters for DRNA

UserTweets
@RNAiAnalyst 9
@WeekHerald 8
@AmericanBanking 7
@TickerReport 7
@ConsumerFeed 6

Recent Tweets for DRNA

TranscriptDaily @TranscriptDaily
-$0.42 EPS Expected for Dicerna Pharmaceuticals $DRNA This Quarter https://t.co/0mVCKWj6dB
May 25th 2018, 5:05pm
dispatchtribune @dispatchtribune
Analysts Anticipate Dicerna Pharmaceuticals $DRNA Will Post Quarterly Sales of $1.79 Million https://t.co/YlQwETg7TA
May 25th 2018, 4:05pm
ledgerzette @ledgerzette
Dicerna Pharmaceuticals $DRNA Expected to Post Earnings of -$0.42 Per Share https://t.co/mf8ro99SR4
May 25th 2018, 12:05pm
TopTickrs @TopTickrs
RT @normanweekly: Godsey & Gibb Associates Has Trimmed Its Visa $V Position; Dicerna Pharmaceuticals $DRNA Shorts Raised By 26.17% - https:…
May 25th 2018, 7:05am
normanweekly @normanweekly
Godsey & Gibb Associates Has Trimmed Its Visa $V Position; Dicerna Pharmaceuticals $DRNA Shorts Raised By 26.17% - https://t.co/T14i3OaDCz
May 25th 2018, 7:05am
ThisLincolnian @ThisLincolnian
Comparing Newron Pharmaceuticals $NWPHF & Dicerna Pharmaceuticals $DRNA https://t.co/YfhNO0lPhe
May 24th 2018, 6:05am
utahherald @utahherald
As Dicerna Pharmaceuticals $DRNA Stock Rose, Ra Capital Management Upped Position; Fundx Investment Group Has Raise… https://t.co/7lRaXcUty7
May 23rd 2018, 11:05am
TickerReport @TickerReport
Dicerna Pharmaceuticals $DRNA Expected to Announce Earnings of -$0.46 Per Share https://t.co/QsBoJliOJV
May 23rd 2018, 5:05am
WatchlistN @WatchlistN
Zacks: Brokerages Anticipate Dicerna Pharmaceuticals $DRNA Will Post Earnings of -$0.46 Per Share https://t.co/ds04LTtoQY
May 23rd 2018, 5:05am
WeekHerald @WeekHerald
Dicerna Pharmaceuticals $DRNA Receives Consensus Rating of “Buy” from Analysts https://t.co/cT1iVD43N7
May 22nd 2018, 11:05am
WeekHerald @WeekHerald
Dicerna Pharmaceuticals $DRNA Expected to Post Quarterly Sales of $1.79 Million https://t.co/8HaE6vl9xX
May 22nd 2018, 6:05am
AmericanBanking @AmericanBanking
Dicerna Pharmaceuticals $DRNA Expected to Post Quarterly Sales of $1.79 Million https://t.co/fbyJHz5HaR #stocks
May 22nd 2018, 2:05am
TickerReport @TickerReport
Dicerna Pharmaceuticals $DRNA Expected to Post Quarterly Sales of $1.79 Million https://t.co/aaxn4o7Fex
May 22nd 2018, 2:05am
dailypoliticaln @dailypoliticaln
Zacks: Analysts Anticipate Dicerna Pharmaceuticals $DRNA Will Announce Quarterly Sales of $1.79 Million https://t.co/ZnUqmqPASx
May 22nd 2018, 2:05am
AmericanBanking @AmericanBanking
Newron Pharmaceuticals $NWPHF vs. Dicerna Pharmaceuticals $DRNA Critical Contrast https://t.co/Xz7I3frfeB #stocks
May 21st 2018, 7:05am
dakotafinancial @dakotafinancial
Newron Pharmaceuticals $NWPHF vs. Dicerna Pharmaceuticals $DRNA Critical Contrast https://t.co/CCGdvQRuDT
May 21st 2018, 7:05am
TheMarketsDaily @TheMarketsDaily
Critical Contrast: Newron Pharmaceuticals $NWPHF & Dicerna Pharmaceuticals $DRNA https://t.co/XdgWPMkIvI
May 21st 2018, 7:05am
AmericanBanking @AmericanBanking
Zacks: Analysts Anticipate Dicerna Pharmaceuticals $DRNA to Post -$0.46 Earnings Per Share https://t.co/x9M78w7sd3 #stocks
May 20th 2018, 9:05pm
WeekHerald @WeekHerald
Zacks: Analysts Anticipate Dicerna Pharmaceuticals $DRNA to Post -$0.46 Earnings Per Share https://t.co/AlaFcOoRpn
May 20th 2018, 9:05pm
ConsumerFeed @ConsumerFeed
-$0.46 EPS Expected for Dicerna Pharmaceuticals $DRNA This Quarter https://t.co/t0L6irPX6o
May 20th 2018, 9:05pm
ConsumerFeed @ConsumerFeed
Dicerna Pharmaceuticals $DRNA Receives $14.20 Average Price Target from Analysts https://t.co/KmfV80KJAt
May 20th 2018, 11:05am
TranscriptDaily @TranscriptDaily
Q2 2018 EPS Estimates for Dicerna Pharmaceuticals Increased by Analyst $DRNA https://t.co/WXQ2RI4NjN
May 20th 2018, 1:05am
ZolmaxNews @ZolmaxNews
Dicerna Pharmaceuticals $DRNA Earns Hold Rating from HC Wainwright https://t.co/c5gB66sEjs
May 19th 2018, 4:05pm
dailypoliticaln @dailypoliticaln
Dicerna Pharmaceuticals $DRNA Earns Hold Rating from HC Wainwright https://t.co/vLeb1bMUg4
May 19th 2018, 3:05pm
WeekHerald @WeekHerald
FY2018 Earnings Forecast for Dicerna Pharmaceuticals Issued By B. Riley $DRNA https://t.co/XjP7Ts2swm
May 19th 2018, 6:05am
TickerReport @TickerReport
FY2018 Earnings Forecast for Dicerna Pharmaceuticals Issued By B. Riley $DRNA https://t.co/x6ymYeDgrx
May 19th 2018, 3:05am
TickerReport @TickerReport
FY2018 Earnings Forecast for Dicerna Pharmaceuticals Issued By B. Riley $DRNA https://t.co/2XIb8BgU0D
May 19th 2018, 3:05am
WatchlistN @WatchlistN
FY2018 Earnings Forecast for Dicerna Pharmaceuticals Issued By B. Riley $DRNA https://t.co/RhdSo7OkAB
May 19th 2018, 2:05am
TickerReport @TickerReport
FY2018 Earnings Forecast for Dicerna Pharmaceuticals Issued By B. Riley $DRNA https://t.co/ATO1R5fdyv
May 19th 2018, 2:05am
ConsumerFeed @ConsumerFeed
Dicerna Pharmaceuticals’ $DRNA “Hold” Rating Reiterated at HC Wainwright https://t.co/PChKQLgvO2
May 18th 2018, 12:05pm
Shas_el @Shas_el
$DRNA up to $250.0 Mil - New Shelf - No Shares Disclosed •
May 18th 2018, 12:05pm
ConsumerFeed @ConsumerFeed
SunTrust Banks Brokers Raise Earnings Estimates for Dicerna Pharmaceuticals $DRNA https://t.co/EsbjdFKFQZ
May 18th 2018, 10:05am
WeekHerald @WeekHerald
SunTrust Banks Brokers Raise Earnings Estimates for Dicerna Pharmaceuticals $DRNA https://t.co/jODVxYhhJu
May 18th 2018, 9:05am
Hypocrites_Oath @Hypocrites_Oath
RT @OpenOutcrier: $DRNA (+0.3% pre) Dicerna gets FDA Orphan Drug Designation for Treatment of primary hyperoxaluria - FDA https://t.co/0c7…
May 18th 2018, 8:05am
OpenOutcrier @OpenOutcrier
$DRNA (+0.3% pre) Dicerna gets FDA Orphan Drug Designation for Treatment of primary hyperoxaluria - FDA https://t.co/0c7G7fUF7G
May 18th 2018, 8:05am
AmericanBanking @AmericanBanking
Brokers Issue Forecasts for Dicerna Pharmaceuticals’ Q2 2018 Earnings $DRNA https://t.co/4SS5jZxVGQ #stocks
May 18th 2018, 7:05am
dakotafinancial @dakotafinancial
Brokers Issue Forecasts for Dicerna Pharmaceuticals’ Q2 2018 Earnings $DRNA https://t.co/fth9Wrurfe
May 18th 2018, 7:05am
ledgerzette @ledgerzette
B. Riley Comments on Dicerna Pharmaceuticals’ FY2018 Earnings $DRNA https://t.co/Y9bxLmoXS3
May 18th 2018, 6:05am
ZolmaxNews @ZolmaxNews
Dicerna Pharmaceuticals $DRNA Shares Down 0.7% https://t.co/KKDTyxvRif
May 18th 2018, 5:05am
TheMarketsDaily @TheMarketsDaily
B. Riley Comments on Dicerna Pharmaceuticals’ FY2018 Earnings $DRNA https://t.co/thN0Bx3ZwJ
May 18th 2018, 2:05am
dakotafinancial @dakotafinancial
B. Riley Comments on Dicerna Pharmaceuticals’ FY2018 Earnings $DRNA https://t.co/Z7xbPuAOqQ
May 18th 2018, 2:05am
TheMarketsDaily @TheMarketsDaily
Dicerna Pharmaceuticals $DRNA Given Consensus Recommendation of “Buy” by Brokerages https://t.co/VazQ3kl8tI
May 17th 2018, 5:05pm
ThisLincolnian @ThisLincolnian
Dicerna Pharmaceuticals $DRNA Given Consensus Recommendation of “Buy” by Brokerages https://t.co/5Yky9GCaHt
May 17th 2018, 5:05pm
kuritzmike @kuritzmike
RT @odibro: $DRNA $250M mixed shelf filed https://t.co/5WsI5Kn8uT
May 17th 2018, 5:05pm
NewsQuantified @NewsQuantified
$DRNA granted orphan status for hyperoxaluria treatment, stock boosts +2.68%, #Dicerna https://t.co/60In2x8YIP
May 17th 2018, 5:05pm
vijay9933 @vijay9933
Hahha sold to you retails ! Does anybody care for ODD $DRNA . 250 m shelf and 25 million shares unloading from inst… https://t.co/rYUYBwbvDV
May 17th 2018, 4:05pm
LanderJesse @LanderJesse
RT @BioRunUp: $DRNA gets FDA Orphan Drug Designation for Treatment of primary hyperoxaluria Just hit FDA database 1 minute ago https://t.…
May 17th 2018, 4:05pm
BioRunUp @BioRunUp
$DRNA gets FDA Orphan Drug Designation for Treatment of primary hyperoxaluria Just hit FDA database 1 minute ago https://t.co/zqGFbqLNCW
May 17th 2018, 4:05pm
TickerReport @TickerReport
Dicerna Pharmaceuticals $DRNA Receives “Hold” Rating from HC Wainwright https://t.co/1lNyUCc4x7
May 17th 2018, 1:05pm
dispatchtribune @dispatchtribune
HC Wainwright Reiterates “Hold” Rating for Dicerna Pharmaceuticals $DRNA https://t.co/qvLTyNOks8
May 17th 2018, 1:05pm

Contact © thinkBiotech LLC 2004 - 2018. All rights reserved.